Health Care & Life Sciences » Pharmaceuticals | Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
6,085.00
4,628.00
5,205.00
3,888
Cost of Goods Sold (COGS) incl. D&A
19.00
89.00
-
-
-
Gross Income
19.00
5,996.00
-
-
-
SG&A Expense
8,885.00
17,311.00
26,402.00
32,632.00
49,058
EBIT
8,904.00
11,315.00
21,906.00
27,676.00
45,463
Unusual Expense
1,444.00
-
-
-
-
Non Operating Income/Expense
-
2.00
36.00
42.00
57
Pretax Income
10,347.00
11,295.00
21,698.00
27,236.00
44,348
Consolidated Net Income
10,347.00
11,295.00
21,698.00
27,236.00
44,348
Net Income
10,347.00
11,295.00
21,698.00
27,236.00
44,348
Net Income After Extraordinaries
10,347.00
11,295.00
21,698.00
27,236.00
44,348
Net Income Available to Common
10,347.00
11,523.00
21,698.00
27,236.00
44,348
EPS (Basic)
0.76
0.84
2.22
1.80
2.13
Basic Shares Outstanding
13,679.80
13,679.80
9,791.70
15,128.20
20,822.60
EPS (Diluted)
0.76
0.84
2.22
1.80
2.13
Diluted Shares Outstanding
13,679.80
13,679.80
9,791.70
15,128.20
20,822.60
EBITDA
8,885.00
11,226.00
21,774.00
27,427.00
45,170
Non-Operating Interest Income
1.00
22.00
244.00
482.00
1,172
Preferred Dividends
-
228.00
-
-
-

About Aeglea BioTherapeutics

View Profile
Address
Barton Oaks Plaza One
Austin Texas 78746
United States
Employees -
Website http://www.aegleabio.com
Updated 07/08/2019
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.